As the most mutated TET family protein is TET2, mutations in TET2 gene are observed in 7 to 23% of AML patients particularly with a normal karyotype and are associated with poorer OS and reduced response to chemotherapy [62, 64, 197]. The gene discussed is TET2; the disease is acute myeloid leukemia.